Recent Updates
Recently added Catalysts
ANIP Positive Sentiment

ANI Pharmaceuticals to Present at Upcoming Investor Conferences

Key Takeaway: ANI Pharmaceuticals announced that CEO Nikhil Lalwani and the executive team will present at upcoming investor conferences. The live and archived webcasts will be available on the company's website, ensuring accessibility for stakeholders. This initiative reflects the company's commitment to engaging with investors and promoting its diverse biopharmaceutical portfolio.
Price reaction · baseline $75.1 (2026-02-23 close) · hit pre-market · 2 other ANIP headline(s) in the window, move may be shared
day 0 close · peak
+2.1%

Market Sentiment Analysis

POSITIVE FACTORS

  • ANI Pharmaceuticals is actively engaging with investors.
  • The company showcases its commitment to transparency through webcasts.
  • Leadership presence at conferences indicates strong company direction.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+19%
120-day peak, hindsight
Typical move
1.6%
average across 3 past catalysts
Lead asset
fluocinolone acetonide
Phase 3 · Diabetic Macular Edema

Full Press Release Details

PRINCETON, N.J., Feb. 24, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, along with members of the Company’s executive leadership team, will present at the following investor conferences:
The live and archived webcasts will be accessible from the Company’s website atwww.anipharmaceuticals.com, under the Investors section under Events and Presentations. The replays of the webcasts will be accessible for 90 days.
About ANIANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company committed to its mission of “Serving Patients, Improving Lives" by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company is focused on delivering sustainable growth through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; its Generics business, which leverages R&D expertise, operational excellence, and U.S.-based manufacturing; and its Brands business. For more information, visitwww.anipharmaceuticals.com.

Investor Relations:Courtney Mogerley, Argot PartnersT: 646-368-8014E:ani@argotpartners.com

Frequently Asked Questions

Who will present at the investor conferences?

Nikhil Lalwani, the CEO, along with the executive leadership team, will present.

Where can I access the conference webcasts?

The webcasts will be available on ANI Pharmaceuticals' website under the Investors section.

How long will the webcasts be accessible?

The archived webcasts will be accessible for 90 days.

What is ANI Pharmaceuticals focused on?

The company focuses on developing innovative therapeutics in various medical fields.

Last updated: Feb 24, 2026